Authors

PARP inhibitors: Treating mCRPC from a genetic basis

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.

Considerations for integrating immunotherapy into earlier stages of bladder cancer

Kristen R. Scarpato, MD, MPH, discusses the potential role of emerging immunotherapy-based combinations in the treatment of BCG-naive, high-risk non–muscle invasive bladder cancer.

Physician Commentary: Do EHR upgrades really enhance patient care?

"Clinicians, now more than ever, have many data entry duties. The clinical encounter’s efficiency is dictated by the ease of the EHR," write Jesse D. Bracamonte, DO, FAAFP, and Michael Underhill, DO.

Considerations for choosing an AI scribe tool

AI scribe solutions are one of the easiest technologies to deploy into existing workflows, writes Vadim Khazan.

Male sexual health and reproductive medicine: All that glitters is not gold

"With the average cost of treatment ranging from $2600 to $3900 per cycle, clinics offering radial wave therapy have an obvious financial incentive to continue marketing despite the lack of evidence of its effectiveness," write Navid Leelani, DO, and Scott D. Lundy, MD, PhD.

Expert explains everything you need to know about lutetium Lu-177 vipivotide tetraxetan for mCRPC

"During treatment with 177Lu-PSMA-617, patients should be counseled to increase oral fluid intake and to void frequently to reduce bladder radiation exposure," writes Stephanie Trexler, PharmD, BCOP.

Understanding molecular phenotypes in RCC may help drive treatment decisions

Benjamin L. Maughan, MD, PharmD, highlights key studies presented at the 2024 ASCO Annual Meeting regarding biomarkers and the evolution of first-line treatments in renal cell carcinoma.

GenesisCare Enrolls First Patients to SpaceOAR Vue Hydrogel Global Clinical Trial

For the first time, the trial will examine the efficacy of SpaceOAR Vue Hydrogel in reducing late gastrointestinal toxicity and improving the quality of life in patients receiving stereotactic body radiotherapy for the treatment of prostate cancer.

Upper tract urothelial carcinoma: An in-depth review for urologists

"On-going innovation will continue to drive UTUC management forward, and with it will come on-going challenges of how to best study a relatively rare disease," write the authors.

Hybrid approach to telehealth effective in rural communities

“A hybrid telehealth approach expands access to specialized care, reduces travel burdens, promotes timely interventions, and enables continuous management of health conditions,” writes Kara Hartl, MD.

Strategies to mitigate impact of intravenous ICM shortage

"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.

Expert examines tech-driven burnout in healthcare

“Health care technology has largely failed to deliver on its promise to make the management of patient care simpler, easier, and less stressful for clinicians,” writes Oron Afek.

What role can automation play in solving the prior authorization issue?

If automation can enhance efficiency and reduce provider dissatisfaction while improving patient health, there’s a strong case for introducing automation into the mix, writes industry expert Eric Demers.

Tax deduction can offset your practice’s cost for new equipment and technology

Section 179 of the IRS Tax Code allows businesses to deduct up to the full purchase price of qualified equipment, technology, software, and other qualifying purchases from their taxes within the same tax year.

Expert explains the crucial role of interoperability in medical billing

"Without interoperability, electronic insurance billing would be nearly impossible. Insurance payers, healthcare providers and claim clearinghouses all rely on interoperability at their core," writes Lisa Taylor.

Dean Laganosky, M.D., named Urology Trailblazer for 2024

This prestigious recognition is given to one urologist or administrator each year who has significantly contributed to the field of urology within the first ten years of their practice.

Trends in coding audits and what physicians can expect

Recent trends in medical audits and what physicians can expect with the CMS changes in 2021 to the documentation of E/M codes.

Laurence Klotz, MD, FRCSC, reveals the impact of micro-ultrasound on his prostate cancer practice

The OPTIMUM randomized trial demonstrated that microultrasonography-guided biopsy is noninferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer, with a streamlined in-office workflow, a manageable learning curve, and substantially lower cost that may help address diagnostic access gaps worldwide.

Christine Ibilibor, MD, highlights study of racial differences in abiraterone use

Data showed that African American men faced significant delays in treatment initiation.

Dr. Xu on why biomarkers are needed for individualized treatment approaches in RCC

“Systemic therapy for RCC has changed very quickly. Every year, it's exciting to see that we're getting new developments, new drug approvals, and changes in the standard of care,” says Wenxin (Vincent) Xu, MD.

Strategies to mitigate impact of intravenous ICM shortage

"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.

Lymph nodes in bladder cancer: Past, present, and future

"Based on the LEA and S1011 trials, it has become clear that patients do not benefit from an extended LND, and a standard bilateral pelvic LND is the standard of care," write Amir Soltani-Tehrani, MD, and Kamal S. Pohar, MD.

UT Money Matters: Are REITs right for your portfolio?

Real estate investment trusts (REITs) offer an alternative asset to stocks or bonds that provide a convenient way to get income from rental properties without the risks and commitment of owning directly.

Emulating target trials using observational evidence to inform clinical decision-making

"The emulation framework lends the design and conduct of observational analyses some of the rigor required for the planning of a randomized trial. In doing so, it provides an innovative and principled approach to improve the evidence base on the comparative effectiveness of interventions," writes Boris Gershman, MD, and Aaron Fleishman, MPH.

Prostate cancer survivor treated at MUSC shares his story

Prostate cancer survivor Larry Ferguson, DMD, participated in a clinical trial at MUSC Hollings Cancer Center.

Advice for limiting malpractice insurance costs

Expert advice for physicians seeking new coverage.

Kidney stone treatment inches toward precision medicine

"As more genes are classified and catalogued, diagnosis and treatment of kidney stones inches further and further toward 'precision medicine,' " write Rutul Patel, DO, MS, and Alexander Small, MD.

What income and estate tax provisions are in the One Big Beautiful Bill Act?

"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.

Unsolved Mystery: Where did COVID-19 come from?

Questions remain surrounding the origin of the global pandemic.

Next-generation sequencing: A reliable tool for the diagnosis and treatment of complicated and recurrent urinary tract infections